Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

2010996 citationsJournal Articlebronze Open Access

Authors

Darcy A. Krueger

Marguerite M. Caré

Kimberly Wilson · Cincinnati Children's Hospital Medical Center

Anna W. Byars

Tarek Sahmoud · Novartis (United States)

David Neal Franz

Abstract

Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).

Topics & Keywords

Tuberous Sclerosis Complex Research

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 19, pp. 1801-1811

DOI: 10.1056/nejmoa1001671

Field-Weighted Citation Impact: 51.44

Command Palette

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

Authors

Abstract

Topics & Keywords

Publication Details